Brian Park, PharmD

Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.

This case report described the first instance of a patient with Crohn disease and relapsing polychondritis who presented with pachymeningitis.

This first-in-class, serotonin (5-HT) 1F receptor agonist is believed to exert its therapeutic effects both centrally and peripherally.

Mylan Pharmaceuticals announced the voluntary recall of one lot of alprazolam 0.5mg tablets to the consumer/user level due to the potential presence of a foreign substance.